Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

106.40 -1.54 (-1.43%)

Streaming Delayed Price Updated: 10:59 AM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Volume	143,894
Open	108.14
Bid (Size)	106.38 (200)
Ask (Size)	106.50 (100)
Prev. Close	107.94
Today's Range	106.34 - 108.14
52wk Range	61.23 - 111.15
Shares Outstanding	142,334,900
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Halozyme Therapeutics (NASDAQ:HALO) Screens Well on High Growth Momentum and Breakout Setup ↗

September 09, 2026

Via Chartmill

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? ↗

September 02, 2026

This biotech innovator could be in only the early chapters of its success story.

Via The Motley Fool

Performance

YTD	+51.3%	+51.3%
1 Month	+3.3%	+3.3%
3 Month	+49.3%	+49.3%
6 Month	+65.5%	+65.5%
1 Year	+39.4%	+39.4%

More News

1 Mid-Cap Stock on Our Watchlist and 2 We Avoid

August 31, 2026

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO) Meets Minervini’s High-Growth Trend Template ↗

August 28, 2026

Via Chartmill

3 Market-Beating Stocks for Long-Term Investors

August 28, 2026

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO) Demonstrates Strong Quality Investing Characteristics Across All Key Metrics ↗

August 20, 2026

Via Chartmill

Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗

June 25, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗

June 03, 2026

Via Chartmill

1 Healthcare Stock with Exciting Potential and 2 We Avoid

August 27, 2026

Via StockStory

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges

August 24, 2026

Via StockStory

Halozyme (HALO) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Via The Motley Fool

The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call

August 13, 2026

Via StockStory

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance

August 07, 2026

Via StockStory

Halozyme Therapeutics (HALO) Shares Skyrocket, What You Need To Know

August 07, 2026

Via StockStory

1 Profitable Stock to Research Further and 2 We Ignore

August 07, 2026

Via StockStory

Halozyme Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales

August 06, 2026

Via StockStory

What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings

August 04, 2026

Via StockStory

3 Growth Stocks Set to Flourish

August 03, 2026

Via StockStory

1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

July 24, 2026

Via StockStory

1 Value Stock Worth Investigating and 2 Facing Headwinds

July 15, 2026

Via StockStory

2 Reasons to Like HALO and 1 to Stay Skeptical

July 10, 2026

Via StockStory

1 Surging Stock for Long-Term Investors and 2 We Brush Off

July 01, 2026

Via StockStory

2 Profitable Stocks Worth Your Attention and 1 We Question

June 18, 2026

Via StockStory

Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today

June 03, 2026

Via StockStory

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?

Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?

Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?

The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market

What is the current price of Halozyme Therapeutics, Inc. - Common Stock?

The current price of Halozyme Therapeutics, Inc. - Common Stock is 106.40

When was Halozyme Therapeutics, Inc. - Common Stock last traded?

The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 09/15/26 10:59 AM ET

What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?

The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 15.14B

How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?

Halozyme Therapeutics, Inc. - Common Stock has 15B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.